Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. to one of three treatment groups: IGF-1R-positive soft-tissue sarcoma (group A) IGF-1R-positive bone sarcomas (group B) or IGF-1R-negative bone KX1-004 and soft-tissue sarcoma (group C). Patients received weekly treatment with cixutumumab (6 mg/kg intravenous) and temsirolimus (25… Continue reading Background Preclinical studies have shown synergistic antitumour activity by inhibition of